First child vaccinated in Phase 2 study of S4V2 shigellosis vaccine

Valneva and LimmaTech Biologics announced the vaccination of the first participant in a Phase 2 pediatric study to evaluate the safety and immunogenicity of the tetravalent shigellosis vaccine candidate, S4V2. This disease, a major contributor to childhood morbidity, could soon be effectively combated thanks to this promising development.

The study, conducted in Kenya, will test two different doses of the S4V2 vaccine and involve approximately 110 nine-month-old infants. Results are expected in the second half of 2025. The project is supported by the Gates Foundation and is part of a strategy to mitigate risks before entering Phase 3. The vaccine has also been granted "Fast Track" status by the FDA, emphasizing the importance of finding a solution to this public health problem.